At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 11 enrolled
Drug / intervention
German cockroach (Blattella germanica) allergenic extractbiological
Likely dose
German cockroach (Blattella germanica) allergenic extract 0.6 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Biomarker-Based Pilot Study of Cockroach Subcutaneous Immunotherapy in Cockroach Sensitive Adults With Asthma and/or Perennial Allergic Rhinitis (ICAC-18)
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Oct 14, 2010·Updated Jun 11, 2014
In Brief
A Phase 1 clinical trial evaluating German cockroach (Blattella germanica) allergenic extract for Asthma and Perennial Allergic Rhinitis. Completed, enrolled 11 participants across 1 site.
Detailed Summary
This trial is a biomarker-based pilot study of the safety of Cockroach Subcutaneous Immunotherapy in Cockroach-sensitive Adults (SCITCO) who have a history of perennial allergic rhinitis, asthma, or both.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma, Perennial Allergic Rhinitis
CountriesUnited States
CollaboratorsInner-City Asthma Consortium
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2010
First PostedOct 2010
Primary CompletionOct 2011
TodayJul 2026
First PostedOct 14, 2010
Enrollment StartSep 1, 2010
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 15.7 years ago
Interventions
German cockroach (Blattella germanica) allergenic extractbiological
Participants received weekly escalating doses of glycerinated German cockroach allergenic extract administered via the subcutaneous route up to a Maximum Study Dose of 0.6 mL of extract at a concentration of 1:20 wt/vol.